• Welcome to Specialised Therapeutics

Australia - Specialised Therapeutics - Page 3

October 15, 2012
  • By stabioadmin
  • 0 Comments

Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)

Lugano, Switzerland and Melbourne, Australia, October 15th, 2012 – Melbourne biopharmaceutical company Specialised Therapeutics Australia (STA) has been granted exclusive commercialisation rights to a new drug for the treatment of NSCLC cachexia-anorexia. This condition is a serious multifactorial disorder which involves muscle wasting and metabolic impairment and commonly affects patients with advanced cancer. STA has reached agreement with Swiss pharmaceutical company Helsinn Healthcare to in-license the novel ghrelin receptor agonist anamorelin for both Australia and New Zealand.

Read More
April 8, 2012
  • By stabioadmin
  • 0 Comments

GLIOLAN® Granted Orphan Drug Status by the Therapeutic Goods Administration

Melbourne, Australia April 2012: A drug which aids neurosurgeons to better visualise and more completely remove malignant brain tumours has been granted orphan drug status by the Therapeutic Goods Administration (TGA). The drug, Gliolan, is currently in-licensed by Melbourne biopharmaceutical company, Specialised Therapeutics Australia (STA) and is currently only available to neurosurgeons via the federal

Read More
August 10, 2011
  • By stabioadmin
  • 0 Comments

Specialised Therapeutics Australia Extends Collaboration with Swiss Helsinn Group

Melbourne, Australia and Lugano, Switzerland, 10 August 2011: Melbourne bio-pharmaceutical company Specialised Therapeutics Australia plans to further expand its oncology portfolio, to include a new product for the prevention of chemotherapy-induced nausea and vomiting (CINV). The Australian company has signed a letter of intent with its Swiss partner, Helsinn Group, to in-license Helsinn’s new compound for

Read More
February 21, 2011
  • By stabioadmin
  • 0 Comments

World Leading Breast Cancer Drug Now Available in New Zealand

Melbourne, Australia and Auckland, New Zealand – 21 February 2011 – New Zealand women now have access to a leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy. The drug, ABRAXANE, uses novel nanoparticle technology to deliver the chemotherapeutic agent to the tumour site and

Read More
October 20, 2010
  • By stabioadmin
  • 0 Comments

Celgene Acquires Abraxis BioScience and Leading Anti-Cancer Drug Abraxane

Melbourne 20 October 2010: Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Abraxis BioScience, Inc. The transaction adds Abraxane®(nanoparticle albumin-bound paclitaxel)  to the company’s existing portfolio of leading cancer products and offers another significant scientific platform that may drive future development.

Read More
June 7, 2010
  • By stabioadmin
  • 0 Comments

PBS Change for Leading Breast Cancer Drug ABRAXANE®

Melbourne, 7 June 2010: Melbourne pharmaceutical company Specialised Therapeutics Australia (STA) wishes to announce a change in the Pharmaceutical Benefits Scheme (PBS) listing for its lead product ABRAXANE® (nanoparticle albumin-bound paclitaxel).

Read More
May 8, 2010
  • By stabioadmin
  • 0 Comments

Study Shows Leading Breast Cancer Drug ABRAXANE® Increases Survival Time for Advanced Pancreatic Cancer

MELBOURNE, May, 2010: An international study of world-leading breast cancer drug ABRAXANE ® (nanoparticle albumin-bound paclitaxel) has shown promising results for patients with advanced pancreatic cancer when used in combination with Gemcitabine.

Read More
March 18, 2010
  • By stabioadmin
  • 0 Comments

ABRAXANE® Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer

LOS ANGELES and MELBOURNE – March 18, 2010: An international lung cancer trial has shown positive results in those patients treated with the leading breast cancer drug ABRAXANE in combination with carboplatin.

Read More
February 8, 2010
  • By stabioadmin
  • 0 Comments

ABRAXANE® Granted Orphan Drug Status for Pancreatic Cancer by Therapeutic Goods Administration

Melbourne, February 2010: A leading Australian breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been granted orphan drug status by the Therapeutic Goods Administration (TGA) for pancreatic cancer.

Read More